Company Astellas Pharma Inc.

Equities

4503

JP3942400007

Pharmaceuticals

Market Closed - Japan Exchange 02:00:00 2024-03-19 am EDT 5-day change 1st Jan Change
1,646 JPY +0.64% Intraday chart for Astellas Pharma Inc. +3.26% -2.34%

Business Summary

Astellas Pharma Inc. specializes in the research, development, manufacturing and marketing of pharmaceutical products. Products are especially for immune diseases, infectious diseases, skin diseases, cancer and urologic disorders.

Net sales are distributed geographically as follows: Japan (28.8%), Americas (34.5%) and others (36.7%).

Number of employees: 14,484

Sales per Business

JPY in Million2022Weight2023Weight Delta
Pharmaceutical
100.0 %
1,296,163 100.0 % 1,518,619 100.0 % +17.16%

Sales per region

JPY in Million2022Weight2023Weight Delta
United States
43.0 %
537,452 41.5 % 652,441 43.0 % +21.40%
Established Markets
23.6 %
315,162 24.3 % 358,407 23.6 % +13.72%
Japan
17.3 %
258,758 20.0 % 262,303 17.3 % +1.37%
International
9.5 %
110,081 8.5 % 144,735 9.5 % +31.48%
Greater China
5.3 %
66,305 5.1 % 80,011 5.3 % +20.67%
Other
1.4 %
8,406 0.6 % 20,722 1.4 % +146.51%

Managers

Managers TitleAgeSince
Chief Executive Officer 61 86-03-31
Director of Finance/CFO 52 Oct. 31
Chairman 63 86-03-31
Compliance Officer - 22-09-30
Chief Tech/Sci/R&D Officer - -
Chief Tech/Sci/R&D Officer - -
Director/Board Member 65 06-08-31
Director/Board Member 63 16-05-31
Director/Board Member 63 83-03-31
Public Communications Contact - -

Members of the board

Members of the board TitleAgeSince
Director/Board Member 67 21-05-31
Director/Board Member 74 17-05-31
Chief Executive Officer 61 86-03-31
Director/Board Member 68 19-05-31
Director/Board Member 63 16-05-31
Director/Board Member 63 -
Director/Board Member 65 06-08-31
Director/Board Member 59 19-05-31
Director/Board Member 63 83-03-31
Director/Board Member 68 18-05-31

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 0 1,809,663,075 1,788,385,938 ( 98.82 %) 16,676,652 ( 0.9215 %) 98.82 %

Shareholders

NameEquities%Valuation
Wellington Management Co. LLP
4.327 %
78,300,954 4.327 % 864 M ¥
BlackRock Fund Advisors
3.662 %
66,273,504 3.662 % 731 M ¥
Nippon Life Insurance Co.
2.851 %
51,588,000 2.851 % 569 M ¥
BlackRock Japan Co. Ltd.
2.478 %
44,846,700 2.478 % 495 M ¥
Mitsubishi UFJ Asset Management Co., Ltd.
1.581 %
28,611,000 1.581 % 316 M ¥
Astellas Pharma Director Incentive Plan
0.8877 %
16,065,000 0.8877 % 177 M ¥
FIL Investments (Japan) Ltd.
0.5626 %
10,180,979 0.5626 % 112 M ¥
BlackRock (Netherlands) BV
0.4359 %
7,887,833 0.4359 % 87 M ¥
BlackRock Investment Management (UK) Ltd.
0.4294 %
7,771,247 0.4294 % 86 M ¥
AMF Tjänstepension AB (Investment Management)
0.3712 %
6,718,000 0.3712 % 74 M ¥
NameEquities%Valuation
RhumbLine Advisers LP
0.001903 %
34,439 0.001903 % 380 000 ¥
Cassady Schiller Wealth Management LLC
0.000039 %
698 0.000039 % 7 702 ¥
PNC Investments LLC
0.000014 %
253 0.000014 % 2 792 ¥
GAMMA Investing LLC
0.000014 %
249 0.000014 % 2 747 ¥
First Horizon Advisors, Inc.
0.000006 %
114 0.000006 % 1 258 ¥
Operose Advisors LLC
0.000005 %
90 0.000005 % 993 ¥

Holdings

NameEquities%Valuation
8,333,333 8.71% 32,999,999 $
7,266,342 3.89% 22,961,641 $
4,968,367 5.03% 10,189,127 $
731,000 0.04% 8,066,059 $
727,200 3.59% 2,837,476 $

Company contact information

Astellas Pharma, Inc.

2-5-1 Nihonbashi-Honcho Chuo-Ku

103-8411, Tokyo

+81 3 3244 3000

http://www.astellas.com
address Astellas Pharma Inc.(4503)

Group companies

NameCategory and Sector
Financial Conglomerates

Sales per region

Trading Rating
Investor Rating
ESG Refinitiv
A
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
1,636 JPY
Average target price
2,142 JPY
Spread / Average Target
+30.93%
Consensus